Arbutus Biopharma Corp (NASDAQ:ABUS) insider Michael J. Mcelhaugh sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $5.01, for a total transaction of $100,200.00. Following the transaction, the insider now directly owns 1,367,457 shares in the company, valued at approximately $6,850,959.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
ABUS opened at $4.04 on Thursday. The company has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.22. Arbutus Biopharma Corp has a twelve month low of $0.82 and a twelve month high of $9.02.
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.06. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.81 million. Equities analysts forecast that Arbutus Biopharma Corp will post -0.87 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Oxford Asset Management LLP acquired a new position in shares of Arbutus Biopharma in the 4th quarter valued at about $61,000. Spark Investment Management LLC bought a new stake in Arbutus Biopharma in the 1st quarter valued at about $28,000. Creative Planning bought a new stake in Arbutus Biopharma in the 2nd quarter valued at about $60,000. Squarepoint Ops LLC bought a new stake in Arbutus Biopharma in the 1st quarter valued at about $43,000. Finally, Wedbush Securities Inc. bought a new stake in Arbutus Biopharma in the 1st quarter valued at about $43,000. 38.12% of the stock is owned by institutional investors and hedge funds.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.
Recommended Story: Management Fee
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.